Generation Bio Co (GBIO)
2.74
-0.68
(-19.88%)
USD |
NASDAQ |
Jun 14, 16:00
2.79
+0.05
(+1.82%)
After-Hours: 20:00
Generation Bio Enterprise Value: -37.01M for June 14, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| June 14, 2024 | -37.01M |
| June 13, 2024 | 8.226M |
| June 12, 2024 | 0.242M |
| June 11, 2024 | -11.73M |
| June 10, 2024 | -20.38M |
| June 07, 2024 | -2.419M |
| June 06, 2024 | 1.573M |
| June 05, 2024 | -0.4232M |
| June 04, 2024 | -11.73M |
| June 03, 2024 | -15.72M |
| May 31, 2024 | -7.741M |
| May 30, 2024 | -3.084M |
| May 29, 2024 | -16.39M |
| May 28, 2024 | -15.06M |
| May 24, 2024 | -15.06M |
| May 23, 2024 | -11.07M |
| May 22, 2024 | 4.899M |
| May 21, 2024 | 6.230M |
| May 20, 2024 | 15.54M |
| May 17, 2024 | 24.19M |
| May 16, 2024 | 31.51M |
| May 15, 2024 | 32.84M |
| May 14, 2024 | 16.21M |
| May 13, 2024 | -30.36M |
| May 10, 2024 | -20.38M |
| Date | Value |
|---|---|
| May 09, 2024 | -2.419M |
| May 08, 2024 | -13.06M |
| May 07, 2024 | -7.867M |
| May 06, 2024 | 3.436M |
| May 03, 2024 | -8.532M |
| May 02, 2024 | -12.52M |
| May 01, 2024 | -25.82M |
| April 30, 2024 | -31.14M |
| April 29, 2024 | -29.81M |
| April 26, 2024 | -26.48M |
| April 25, 2024 | -19.17M |
| April 24, 2024 | -20.50M |
| April 23, 2024 | -2.548M |
| April 22, 2024 | -32.47M |
| April 19, 2024 | -33.13M |
| April 18, 2024 | -34.46M |
| April 17, 2024 | -21.17M |
| April 16, 2024 | -11.19M |
| April 15, 2024 | 26.71M |
| April 12, 2024 | 26.71M |
| April 11, 2024 | 46.65M |
| April 10, 2024 | 27.37M |
| April 09, 2024 | 45.28M |
| April 08, 2024 | 69.88M |
| April 05, 2024 | 43.95M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-230.75M
Minimum
Oct 27 2023
2.120B
Maximum
Dec 02 2020
390.37M
Average
39.66M
Median
Oct 06 2022
Enterprise Value Benchmarks
| CEL-SCI Corp | 65.10M |
| AIM ImmunoTech Inc | 15.35M |
| IGC Pharma Inc | 25.36M |
| NovaBay Pharmaceuticals Inc | 3.382M |
| Protalix BioTherapeutics Inc | 55.51M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -74.54M |
| Revenue (Quarterly) | 4.059M |
| Total Expenses (Quarterly) | 24.76M |
| EPS Diluted (Quarterly) | -1.12 |
| Profit Margin (Quarterly) | -1.84K% |
| Earnings Yield | -93.07% |
| Normalized Earnings Yield | -61.79 |